Zhenhuan Zhang

3.3k citations
86 papers · 2.5k indexed · h-index 27

Zhenhuan Zhang

85 papers receiving 2.5k citations

Peers

Zhenhuan Zhang
Comparison fields: 5 of 140
  • Cancer Research 524
  • Oncology 842
  • Molecular Biology 1.4k
  • Genetics 489
  • Immunology 194
Replace Ying Jiang with:
Ying Jiang China
Sven Bilke United States
Takashi Sugihara Japan
Helen H. Wang United States
Amit Arora India
Veerabhadran Baladandayuthapani United States
Håvard E. Danielsen Norway
Xiaoli Yu China
Syed Haider United Kingdom
Zhenhuan Zhang relative to Ying Jiang China Ying Jiang's profile →
Citations per field
00.5×2.6×
Ying Jiang · 1×
Citations per year

Countries citing papers authored by Zhenhuan Zhang

Since Specialization
Citations

This map shows the geographic impact of Zhenhuan Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenhuan Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenhuan Zhang more than expected).

Fields of papers citing papers by Zhenhuan Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenhuan Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenhuan Zhang. The network helps show where Zhenhuan Zhang may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Zhenhuan Zhang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Zhenhuan Zhang Line = papers co-authored together Zhenhuan Zhang links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20249
2 202412
3 20231
4 20235
5 20232
6 20216
7 20204
8 20176
9 201522
10 20144
11 201312
12 20139
13 201212
14 20128
15
Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse.
200910
16 200818
17 200654
18 200590
19 2003125
20 200315

About Zhenhuan Zhang

Zhenhuan Zhang is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 86 papers that have together received 2.5k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (13 papers), Genomics and Chromatin Dynamics (8 papers), Effects of Radiation Exposure (7 papers), DNA Repair Mechanisms (6 papers), HER2/EGFR in Cancer Research (6 papers), Breast Cancer Treatment Studies (5 papers), Cell death mechanisms and regulation (5 papers) and Radiation Therapy and Dosimetry (5 papers). The work is most often cited by research in Cancer Research (524 citations), Oncology (842 citations) and Molecular Biology (1.4k citations). Zhenhuan Zhang has collaborated with scholars based in United States, China and Japan. Frequent co-authors include Hirotaka Iwase, Hiroko Yamashita, Tatsuya Toyama, Hiroshi Sugiura, Shunzo Kobayashi, Maho Hamaguchi, Yukio Ando, Keiko Mita, Yasuo Hara and Mariko Nishio. Their work appears in journals such as Advances in experimental medicine and biology, Breast Cancer Research, PLoS ONE, Clinical Cancer Research and Japanese Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026